# PT-141 Research: Mechanism, the HSDD Trials, and Early Male Data > What the PT-141 research record shows: central MC4R/MC3R mechanism, the RECONNECT Phase 3 HSDD trials in women, the modest measured efficacy, and the early, off-label male erectile data. Mechanism first, then the approved HSDD evidence in women, the modest efficacy numbers read honestly, and the early male erectile work framed as the investigational data it is. ## Start here PT-141 works in the brain, not on blood vessels. It switches on melanocortin receptors (MC4R and MC3R) in deep brain regions that shape sexual desire, which is a fundamentally different approach from the erectile-blood-flow drugs. The strongest evidence is in premenopausal women with distressing low desire, where two large trials showed a real but small improvement. In men, the data are old and early-stage, and the drug is not approved for them. The sections below walk through each of these, with every number tied to a study. ## PT-141 Mechanism of Action: Central Melanocortin Signaling PT-141 is an alpha-MSH analogue that agonizes (activates) melanocortin MC4R and MC3R receptors in the hypothalamus — including the medial preoptic area — and the limbic system [1]. By engaging these central circuits it recruits dopaminergic signaling linked to appetitive, desire-driven sexual behavior, rather than acting on vascular tone the way PDE-5 inhibitors do [1]. The preclinical record is specific about which behaviors change. In female rats, PT-141 selectively increased appetitive solicitational behaviors — the proceptive, desire-driven kind — without affecting lordosis, pacing, or general motor activity [2]. It was the first reported pharmacological agent acting on appetitive female sexual behavior, evidence that central melanocortin systems help regulate desire itself [2]. In male rats and nonhuman primates, systemic dosing produced penile erections and activated hypothalamic neurons (measured as increased c-Fos), again pointing to a central mechanism [1]. The most direct human mechanistic evidence comes from a randomized, double-blind, placebo-controlled crossover fMRI study of 31 premenopausal women with HSDD: MC4R agonism significantly increased sexual desire for up to 24 hours and altered task-based brain processing of erotic stimuli, enhancing amygdala–insula functional connectivity [5]. A 2025 study in female Syrian hamsters refined the picture from the other direction — MC3R/MC4R messenger RNA was concentrated in ventral tegmental area dopamine neurons, but bremelanotide did not change melanocortin-receptor expression in the mesolimbic dopamine system and did not enhance sexual reward in a conditioned-place-preference test, suggesting it does not act on the VTA-to-nucleus-accumbens reward circuit [14]. ## PT-141 in Female Sexual Desire: The Approved HSDD Indication The only FDA-approved use of PT-141 is **PT-141 for women** — specifically, acquired, generalized HSDD in premenopausal women [3]. Approval rests on RECONNECT: two identical Phase 3 randomized controlled trials enrolling 1,267 premenopausal women with HSDD [3]. Bremelanotide 1.75 mg subcutaneous as-needed met both coprimary endpoints, improving desire (integrated FSFI-desire +0.35, P<.001) and reducing desire-related distress (integrated FSDS-DAO item 13 -0.33, P<.001) over 24 weeks [3]. A 52-week open-label extension enrolling 684 women found no new safety signals and sustained desire improvements, with nausea, flushing, and headache the most common drug-related events [4]. The earlier dose-finding work that selected 1.75 mg compared subcutaneous 0.75, 1.25, and 1.75 mg in premenopausal women with female sexual dysfunction [9], and a Phase 2b responder analysis characterized the proportion of women reaching clinically meaningful improvement across doses [10]. "Acquired" and "generalized" matter: the indication is for women whose low desire is a change from a prior baseline and is not limited to certain situations or partners. ## What the Trials Measured: PT-141 Efficacy Endpoints Read for **PT-141 benefits**, the honest summary is this: the approved trials met their endpoints, and the effect sizes were small. Integrated FSFI-desire improved by +0.35 and FSDS-DAO item-13 distress fell by -0.33 versus placebo — statistically significant at P<.001 in both RECONNECT trials, but modest in absolute terms [3]. The 52-week extension showed the desire benefit held up over a year of as-needed use rather than fading [4]. That modesty is contested in the literature, not hidden by it. Critical re-analyses argue the trial effects on desire and distress, while statistically significant, are small enough to question their clinical meaningfulness and the choice of outcome measures [3]. This digest presents the endpoints as measured and flags the debate rather than resolving it — the numbers are real, and so is the argument about what they mean. The efficacy story is best read alongside the [PT-141 side effects documented in trials](/side-effects), because tolerability is what shaped real-world persistence. ## PT-141 in Men: Early Erectile Research (Off-Label / Investigational) Interest in **PT-141 for men** traces to early-2000s erectile-dysfunction work, and it is essential to be precise: none of it is approved, and the drug is off-label in men. Intranasal PT-141 in healthy men and PDE-5-inhibitor-responsive ED patients produced a dose-dependent erectile response that was statistically significant versus placebo at doses above 7 mg, with the first erection reported at roughly 30 minutes [6]. Subcutaneous dosing was then evaluated in healthy men and in patients with an inadequate response to sildenafil, characterizing the pharmacokinetics and erectile pharmacodynamics that informed later development [7]. A separate study examined co-administering low-dose intranasal PT-141 with sildenafil, pairing a central melanocortin agonist with a peripheral PDE-5 inhibitor [8]. Two cautions belong on this evidence. First, it is early-phase and dated; the program that reached approval went a different direction (HSDD in women), and no Phase 3 male erectile indication exists. Second, a 2023 Expression of Concern was issued for a 2008 bremelanotide erectile-dysfunction salvage study, so that particular result should be treated as disputed [3]. Described accurately, male/erectile use is investigational and off-label — never established, never approved. The [early erectile research in men](/research#male) is presented here as a historical and pharmacological record, not a use case. --- A clinician's measured read of the bremelanotide record — the confirmed trial findings raised plainly, the tolerability and contraindication facts pressed in first, and the unverified field reports kept off to one side; no clinic behind the surface and nothing here dosed, dispensed, or sold.